Images List Premium Download Classic

Expression Vector

Expression Vector-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Enzymes that cleave non-glycosidic ether bonds between lignins or derivatives thereof and saccharides
Tethys Research Llc
January 11, 2018 - N°20180010113

The patent application relates to isolated polypeptides that specifically cleave non-glycosidic ether bonds between lignins or derivatives thereof and saccharides, and to cdnas encoding the polypeptides. The patent application also relates to nucleic acid constructs, expression vectors and host cells comprising the cdnas, as well as methods of producing and using the isolated polypeptides for treating pulp and biomass to ...
A method for producing a recombinant allotypespecific rabbit monoclonal antibody
Abcam Plc
January 11, 2018 - N°20180009875

A method for cloning a full length coding sequence for a light chain of a rabbit monoclonal antibody is provided. In some embodiments, this method may involve: fusing a b cell from a rabbit having a b4 allotype with a 240e cell or a derivative thereof to produce a hybridoma, wherein the b cell and the hybridoma produce a monoclonal ...
Factor viii proteins having ancestral sequences, expression vectors, and uses related thereto
Georgia Tech Research Corporation
January 11, 2018 - N°20180009873

This disclosure relates to recombinant or chimeric fviii proteins, variants, and vectors encoding the proteins containing one or more ancestral mutations. In certain embodiments, one or more protein domains comprise amino acid sequences that are derived from ancestrally reconstructed amino acid sequences. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising the proteins or vectors and related methods of ...
Expression Vector Patent Pack
Download 166+ patent application PDFs
Expression Vector Patent Applications
Download 166+ Expression Vector-related PDFs
For professional research & prior art discovery
inventor
  • 166+ full patent PDF documents of Expression Vector-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Anti-mesothelin antibodies and uses thereof
Sri International
January 04, 2018 - N°20180002439

The present disclosure provides isolated nanobodies based on camelid vhh domains that specifically bind to mesothelin with high affinity. Also disclosed are conjugate constructs comprising the isolated nanobodies derivatized to allow conjugation to or that are conjugated to accessory moieties, such as biologically active moieties (e. G., a cytotoxin, a non-cytotoxic drug, a radioactive agent, a protein, or an enzyme) ...
Neutralizing gp41 antibodies and their use
The United States Of America, As Represented By The Secretary, Department Of Health And Human
January 04, 2018 - N°20180002406

Monoclonal neutralizing antibodies are disclosed that specifically bind to the hiv-1 gp41 membrane-proximal external region (mper). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the ...
Jc polyomavirus vlp (virus-like particle) with a targeting peptide
Life Science Inkubator Gmbh
January 04, 2018 - N°20180002384

The disclosure relates to a fusion protein comprising at least a first and a second peptide, wherein —the second peptide comprises a targeting region and a first and a second interaction region, —the second peptide is located on the surface of the fusion protein; —the second peptide comprises at least two interaction pairs, wherein an interaction pair ...
Expression Vector Patent Pack
Download 166+ patent application PDFs
Expression Vector Patent Applications
Download 166+ Expression Vector-related PDFs
For professional research & prior art discovery
inventor
  • 166+ full patent PDF documents of Expression Vector-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Endoglucanase variants and polynucleotides encoding same
Novozymes A/s
December 28, 2017 - N°20170369860

The present invention relates to endoglucanase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, expression vectors, and recombinant host cells comprising the polynucleotides; and methods of using the variants.
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
Biomed Valley Discoveries, Inc.
December 28, 2017 - N°20170369585

Polypeptides and proteins that specifically bind to and immunologically recognize cd276 are disclosed. Chimeric antigen receptors (cars), anti-cd276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in ...
Hyperglycosylated binding polypeptides
Genzyme Corporation
December 28, 2017 - N°20170369584

Provided are binding polypeptides (e. G., antibodies), and effector moiety conjugates thereof, comprising a ch1 domain (e. G., a human igg1 ch1 domain), wherein the ch1 domain has an engineered n-linked glycosylation site at amino acid position 114, according to kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding ...
Recombinant cd74 polypeptides
The United States Government As Represented By The Department Of Veterans Affairs
December 28, 2017 - N°20170369577

Disclosed are recombinant cd74 polypeptides mutated relative to the naturally occurring cd74 polypeptides with improved properties such as binding of cd74 ligands such as mif and rtl1000 as well as polynucleotides that encode the polypeptides, expression vectors comprising the polynucleotides, bacteria that include the expression vectors, and methods of making the recombinant polypeptides.
Met receptor agonist proteins
Universita' Degli Studi Di Pavia
December 28, 2017 - N°20170369545

Disclosed are proteins derived from the hgf/sf which are able to induce activation of the tyrosine kinase receptor met and their uses, in particular to promote tissue regeneration. Further disclosed are nucleic acid molecules coding such protein, expression vectors containing such nucleic acid molecule, host cells containing such expression vectors, and related compositions.
Methods to produce rod-derived cone viability factor (rdcvf)
Genzyme Corporation
December 28, 2017 - N°20170369541

The invention is related to methods of producing rod-derived cone viability factor (rdcvf). This invention also relates to the treatment of an ocular disease in a mammal using rdcvf. Also provided are expression vectors for high secreted expression of rdcvf of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes
The United States Of America, As Represented By The Secretary, Department Of Health And Human
December 28, 2017 - N°20170369535

The invention provides a pseudomonas exotoxin a (pe) comprising an amino acid sequence having a substitution of one or more b-cell and/or t-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of ...
Expression Vector Patent Pack
Download 166+ patent application PDFs
Expression Vector Patent Applications
Download 166+ Expression Vector-related PDFs
For professional research & prior art discovery
inventor
  • 166+ full patent PDF documents of Expression Vector-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Insecticidal proteins and methods for their use
Pioneer Hi-bred International, Inc.
December 28, 2017 - N°20170367349

Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial ...
Site-directed crispr/recombinase compositions and methods of integrating transgenes
Applied Stemcell, Inc.
December 21, 2017 - N°20170362611

Disclosed herein are targeted chimeric polypeptides, compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy and cell therapy techniques. The chimeric polypeptide includes a crispr-cas domain and a recombinase domain.
Methods for producing abienol
Dsm Ip Assets B.v.
December 21, 2017 - N°20170362583

The present disclosure relates to a novel method, expression vectors, and host cells for producing abienol by converting geranylgeranyl diphosphate (ggpp) to abienol in the presence of a combination of a class ii diterpene synthase and a bifunctional class i/ii abienol synthase.
Tem-1 diagnostic antibodies
Morphotek, Inc.
December 21, 2017 - N°20170362335

Described herein are anybodies, and antigen-binding fragments thereof, that are specific for tumor endothelial marker 1 (tem-1), related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing tem-1-expressing cancers (such as melanoma, sarcoma, bladder cancer or ...
Method and pharmaceutical composition for use in the treatment of cancer
Assistance Publique-hopitaux De Paris
December 21, 2017 - N°20170362302

The present invention relates to a soluble peptide comprising the amino acids sequence: krfyvvmwkk (seq id no: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic ...
Mutant nq-rhodopsin kr 2
Cea Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives
December 21, 2017 - N°20170362281

The invention relates to mutant nq-rhodopsin having potassium pumping properties, nucleic acid constructs encoding same, expression vectors carrying the nucleic acid construct, cells comprising said nucleic acid construct or expression vector, and their respective uses.
Vlp with a fusion protein
Life Science Inkubator Betriebs Gmbh & Co. Kg
December 21, 2017 - N°20170362279

The disclosure relates to a fusion protein comprising a vp1 binding protein and an exogenous peptide, wherein the exogenous peptide comprises a cargo-securing peptide (csp) and/or an endosome translocating peptide (etp) and to virus like particles (vlp) comprising the fusion protein for use as drug delivery system. Also provided are polynucleotides encoding the fusion protein, suitable expression vectors, host ...
Novel immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants
Sanofi Pasteur
December 21, 2017 - N°20170360923

The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, ...
Loading